1.2023 Korean Association of Urogenital Tract Infection and Inflammation guidelines for gonococcal infection
Hee Jo YANG ; Hyuk Min LEE ; Seung-Ju LEE ; Jin Bong CHOI ; Sangrak BAE ; Jae Hung JUNG ; Tae Wook KANG ; Eu Chang HWANG
Investigative and Clinical Urology 2024;65(1):1-8
		                        		
		                        			
		                        			 The incidence of gonorrhea has increased significantly in recent years in the United States, especially among sexually active twenty-year-olds. Although the incidence of gonorrhea has decreased in Korea since the early 2000s, it is still common among people in their twenties. Nucleic acid amplification test (NAAT) is the most sensitive diagnostic test for detecting gonococcal infection. Gram-staining is a simple and useful laboratory test for diagnosing symptomatic male gonococcal urethritis. Although bacterial culture can be used to detect antimicrobial susceptibility, its sensitivity is lower than that of NAAT. Treatment for uncomplicated gonorrhea infection is a single intramuscular injection of ceftriaxone 500 mg. Doxycycline (100 mg twice daily for 7 days) is added if there is a possibility of co-infection with chlamydia. If ceftriaxone is difficult to use, spectinomycin 2 g can be injected intramuscularly in Korea. Patients with gonorrhea should have repeated examinations within three months at the exposure site because of a high risk of re-infection. A person diagnosed with gonorrhea should discuss the nature of the infection, the importance of informing partners, when sexual activity can resume, and how to reduce the risk of sexually transmitted infections. 
		                        		
		                        		
		                        		
		                        	
2.Contemporary Statistics of Acute Ischemic Stroke and Transient Ischemic Attack in 2021: Insights From the CRCS-K-NIH Registry
Do Yeon KIM ; Tai Hwan PARK ; Yong-Jin CHO ; Jong-Moo PARK ; Kyungbok LEE ; Minwoo LEE ; Juneyoung LEE ; Sang Yoon BAE ; Da Young HONG ; Hannah JUNG ; Eunvin KO ; Hyung Seok GUK ; Beom Joon KIM ; Jun Yup KIM ; Jihoon KANG ; Moon-Ku HAN ; Sang-Soon PARK ; Keun-Sik HONG ; Hong-Kyun PARK ; Jeong-Yoon LEE ; Byung-Chul LEE ; Kyung-Ho YU ; Mi Sun OH ; Dong-Eog KIM ; Dong-Seok GWAK ; Soo Joo LEE ; Jae Guk KIM ; Jun LEE ; Doo Hyuk KWON ; Jae-Kwan CHA ; Dae-Hyun KIM ; Joon-Tae KIM ; Kang-Ho CHOI ; Hyunsoo KIM ; Jay Chol CHOI ; Joong-Goo KIM ; Chul-Hoo KANG ; Sung-il SOHN ; Jeong-Ho HONG ; Hyungjong PARK ; Sang-Hwa LEE ; Chulho KIM ; Dong-Ick SHIN ; Kyu Sun YUM ; Kyusik KANG ; Kwang-Yeol PARK ; Hae-Bong JEONG ; Chan-Young PARK ; Keon-Joo LEE ; Jee Hyun KWON ; Wook-Joo KIM ; Ji Sung LEE ; Hee-Joon BAE ;
Journal of Korean Medical Science 2024;39(34):e278-
		                        		
		                        			
		                        			 This report presents the latest statistics on the stroke population in South Korea, sourced from the Clinical Research Collaborations for Stroke in Korea-National Institute for Health (CRCS-K-NIH), a comprehensive, nationwide, multicenter stroke registry. The Korean cohort, unlike western populations, shows a male-to-female ratio of 1.5, attributed to lower risk factors in Korean women. The average ages for men and women are 67 and 73 years, respectively.Hypertension is the most common risk factor (67%), consistent with global trends, but there is a higher prevalence of diabetes (35%) and smoking (21%). The prevalence of atrial fibrillation (19%) is lower than in western populations, suggesting effective prevention strategies in the general population. A high incidence of large artery atherosclerosis (38%) is observed, likely due to prevalent intracranial arterial disease in East Asians and advanced imaging techniques.There has been a decrease in intravenous thrombolysis rates, from 12% in 2017–2019 to 10% in 2021, with no improvements in door-to-needle and door-to-puncture times, worsened by the coronavirus disease 2019 pandemic. While the use of aspirin plus clopidogrel for noncardioembolic stroke and direct oral anticoagulants for atrial fibrillation is well-established, the application of direct oral anticoagulants for non-atrial fibrillation cardioembolic strokes in the acute phase requires further research. The incidence of early neurological deterioration (13%) and the cumulative incidence of recurrent stroke at 3 months (3%) align with global figures. Favorable outcomes at 3 months (63%) are comparable internationally, yet the lack of improvement in dependency at 3 months highlights the need for advancements in acute stroke care. 
		                        		
		                        		
		                        		
		                        	
3.Efficacy and Safety of Lurasidone vs. Quetiapine XR in Acutely Psychotic Patients With Schizophrenia in Korea: A Randomized, Double-Blind, Active-Controlled Trial
Se Hyun KIM ; Do-Un JUNG ; Do Hoon KIM ; Jung Sik LEE ; Kyoung-Uk LEE ; Seunghee WON ; Bong Ju LEE ; Sung-Gon KIM ; Sungwon ROH ; Jong-Ik PARK ; Minah KIM ; Sung Won JUNG ; Hong Seok OH ; Han-yong JUNG ; Sang Hoon KIM ; Hyun Seung CHEE ; Jong-Woo PAIK ; Kyu Young LEE ; Soo In KIM ; Seung-Hwan LEE ; Eun-Jin CHEON ; Hye-Geum KIM ; Heon-Jeong LEE ; In Won CHUNG ; Joonho CHOI ; Min-Hyuk KIM ; Seong-Jin CHO ; HyunChul YOUN ; Jhin-Goo CHANG ; Hoo Rim SONG ; Euitae KIM ; Won-Hyoung KIM ; Chul Eung KIM ; Doo-Heum PARK ; Byung-Ook LEE ; Jungsun LEE ; Seung-Yup LEE ; Nuree KANG ; Hee Yeon JUNG
Psychiatry Investigation 2024;21(7):762-771
		                        		
		                        			 Objective:
		                        			This study was performed to evaluate the efficacy and safety of lurasidone (160 mg/day) compared to quetiapine XR (QXR; 600 mg/day) in the treatment of acutely psychotic patients with schizophrenia. 
		                        		
		                        			Methods:
		                        			Patients were randomly assigned to 6 weeks of double-blind treatment with lurasidone 160 mg/day (n=105) or QXR 600 mg/day (n=105). Primary efficacy measure was the change from baseline to week 6 in Positive and Negative Syndrome Scale (PANSS) total score and Clinical Global Impressions severity (CGI-S) score. Adverse events, body measurements, and laboratory parameters were assessed. 
		                        		
		                        			Results:
		                        			Lurasidone demonstrated non-inferiority to QXR on the PANSS total score. Adjusted mean±standard error change at week 6 on the PANSS total score was -26.42±2.02 and -27.33±2.01 in the lurasidone and QXR group, respectively. The mean difference score was -0.91 (95% confidence interval -6.35–4.53). The lurasidone group showed a greater reduction in PANSS total and negative subscale on week 1 and a greater reduction in end-point CGI-S score compared to the QXR group. Body weight, body mass index, and waist circumference in the lurasidone group were reduced, with significantly lower mean change compared to QXR. Endpoint changes in glucose, cholesterol, triglycerides, and low-density lipoprotein levels were also significantly lower. The most common adverse drug reactions with lurasidone were akathisia and nausea. 
		                        		
		                        			Conclusion
		                        			Lurasidone 160 mg/day was found to be non-inferior to QXR 600 mg/day in the treatment of schizophrenia with comparable efficacy and tolerability. Adverse effects of lurasidone were generally tolerable, and beneficial effects on metabolic parameters can be expected. 
		                        		
		                        		
		                        		
		                        	
4.Use of the Monoclonal Antibody Regdanvimab to Treat Patients Hospitalized with COVID-19:Real-World Data during the Delta Variant Predominance
Yee Gyung KWAK ; Je Eun SONG ; Jieun KANG ; Jiyeon KANG ; Hyung Koo KANG ; Hyeon-Kyoung KOO ; Hye Kyeong PARK ; Sang Bong CHOI ; Hyuk Pyo LEE ; Myung Jin LEE ; Baek-Nam KIM
Infection and Chemotherapy 2022;54(4):781-786
		                        		
		                        			
		                        			 Regdanvimab is the only monoclonal antibody available in Korea that targets severe acute respiratory syndrome coronavirus 2. We retrospectively evaluated the clinical characteristics of 374 adults hospitalized with coronavirus disease 2019 (COVID-19) who were treated with regdanvimab from September through December 2021. In total, 322 (86.1%) patients exhibited risk factors for disease progression. Most patients (91.4%) improved without additional treatment. No patient died or was transferred to intensive care. This study shows that regdanvimab prevented disease progression in high-risk patients with mild to moderate COVID-19 infections during Delta variant predominance. 
		                        		
		                        		
		                        		
		                        	
5.A Preliminary Study of the Association between SOX17 Gene Variants and Intracranial Aneurysms Using Exome Sequencing
Jeong Jin PARK ; Bong Jun KIM ; Dong Hyuk YOUN ; Hyuk Jai CHOI ; Jin Pyeong JEON
Journal of Korean Neurosurgical Society 2020;63(5):559-565
		                        		
		                        			 Objective:
		                        			Conflicting results regarding SOX17 genes and the risk of intracranial aneurysms (IA) exist in the Korean population, although significant positive correlations were noted in genome-wide association studies in European and Japanese populations. Therefore, we aimed to investigate an association between SOX17 gene variants and IA using exome sequencing data. 
		                        		
		                        			Methods:
		                        			This study included 26 age-gender matched IA patients and 26 control subjects. The SOX17 gene variants identified from whole-exome sequencing data were examined. Genetic associations to estimate odds ratio (OR) and 95% confidence interval (CI) were performed using the software EPACTS. 
		                        		
		                        			Results:
		                        			The mean age of the IA and control groups were 51.0±9.3 years and 49.4±14.3 years, respectively (p=0.623). Seven variants of SOX17, including six single nucleotide polymorphisms and one insertion and deletion, were observed. Among these variants, rs12544958 (A>G) showed the most association with IA, but the association was not statistically significant (OR, 1.97; 95% CI, 0.81-4.74; p=0.125). Minor allele frequencies of the IA patients and controls were 0.788 and 0.653, respectively. None of the remaining variants were significantly associated with IA formation. 
		                        		
		                        			Conclusion
		                        			No significant association between SOX17 gene variants and IA were noted in the Korean population. A large-scale exome sequencing study is necessary to investigate any Korean-specific genetic susceptibility to IA. 
		                        		
		                        		
		                        		
		                        	
6.Comparison of Psychological Characteristics of Lesch Types 2 (Anxiety Model) and 3 (Depressive Model) Alcoholism
Sae Heon JANG ; Min Ho CHANG ; Young Myo JAE ; Jin Hyuk CHOI ; Gyeong Hwan LEE
Mood and Emotion 2019;17(2):49-56
		                        		
		                        			
		                        			BACKGROUND: Lesch types 2 (L2, anxiety model) and 3 (L3, depressive model) of alcoholism exhibit different responses to anti-craving agents, and most treatment guidelines provide differential treatment strategies for bipolar depression (DEP) and unipolar DEP. We compare the psychological characteristics of L2 and L3 alcoholism and between the unipolar and bipolar subgroups.METHODS: We reviewed medical records of patients who were diagnosed with alcohol use disorder using the DSM-5 diagnostic criteria and classified as L2 and L3 using Lesch Alcohol typology software. All patients completed self-report scales (Alcohol Use Disorders Identification Test [AUDIT], Beck Anxiety Inventory [BAI], Beck Depression Inventory-II [BDI-II], and Korean Symptom Checklist-95 [KSCL95]). The data were analyzed using descriptive statistics, the Wilcoxon Rank-Sum test, and ANOVA.RESULTS: Of the 43 patients, 23 were assigned L2, and 20 were assigned L3. The scores for the KSCL95 subscales fell generally in the increasing order of the L2-unipolar (L2U, n=10), L2-bipolar (L2B, n=13), L3-unipolar (L3U, n=11), and L3-bipolar (L3B, n=9) types. The L3B scores were greater than the L3U scores for most KSCL95 subscales, by contrast with the DEP and BAI scores.CONCLUSION: We found psychological differences between L2 and L3 and identified the unique psychological characteristics for each subgroup by polarity. The psychological characteristics of these subgroups of alcohol use disorder may help improve the treatment success rates through individualized treatment strategies.
		                        		
		                        		
		                        		
		                        			Alcoholism
		                        			;
		                        		
		                        			Anxiety
		                        			;
		                        		
		                        			Bipolar Disorder
		                        			;
		                        		
		                        			Depression
		                        			;
		                        		
		                        			Depressive Disorder
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Medical Records
		                        			;
		                        		
		                        			Weights and Measures
		                        			
		                        		
		                        	
7.Effect of Korean Herbal Formula (Modified Ojayeonjonghwan) on Androgen Receptor Expression in an Aging Rat Model of Late Onset Hypogonadism.
Sae Woong CHOI ; Seung Hwan JEON ; Eun Bi KWON ; Guan Qun ZHU ; Kyu Won LEE ; Jin Bong CHOI ; Hyun Cheol JEONG ; Kang Sup KIM ; Sang Rak BAE ; Woong Jin BAE ; Su Jin KIM ; Hyuk Jin CHO ; U Syn HA ; Sung Hoo HONG ; Sung Yeoun HWANG ; Sae Woong KIM
The World Journal of Men's Health 2019;37(1):105-112
		                        		
		                        			
		                        			PURPOSE: Testosterone replacement therapy is an effective treatment for late-onset hypogonadism (LOH) despite a few contraindications and side-effects. The aim of this study was to determine whether modified Ojayeonjonghwan (KH-204, Korean herbal formula) improved LOH. KH-204 is a strong antioxidant herbal formula. We evaluated the effect of Korean herbal prescription on androgen receptor (AR) expression in an aged rat model of LOH. MATERIALS AND METHODS: Eighteen-month-old rats were used as aged LOH rat models. Eighteen Sprague-Dawley rats were randomly divided into three equal groups of six animals each and treated with one of the following: 1) normal control group (oral administration with distilled water, n=6), 2) KH-204 200 group (oral administration with 200 mg/kg of KH-204, n=6), and 3) KH-204 400 group (oral administration with 400 mg/kg of KH-204, n=6). After four weeks of treatment (once daily, distilled water or KH-204), serum testosterone levels, changes in testicular and epididymal weight, Western blotting analysis of AR expression and measurement of oxidative stress were examined. RESULTS: Treatment with the herbal formulation KH-204 200 mg/kg and 400 mg/kg (1) increased the weights of testis and epididymis; (2) increased the level of serum testosterone; (3) increased the level of superoxide dismutase and reduced the level of 8-hydroxy-20-deoxyguanosine; and (4) upregulated AR expression in testicular tissue. CONCLUSIONS: KH-204 might be an effective alternative for LOH. It improves antioxidant mechanisms and increases testicular AR expression without side-effects.
		                        		
		                        		
		                        		
		                        			Aging*
		                        			;
		                        		
		                        			Animals
		                        			;
		                        		
		                        			Blotting, Western
		                        			;
		                        		
		                        			Epididymis
		                        			;
		                        		
		                        			Hypogonadism*
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Models, Animal*
		                        			;
		                        		
		                        			Oxidative Stress
		                        			;
		                        		
		                        			Phytotherapy
		                        			;
		                        		
		                        			Prescriptions
		                        			;
		                        		
		                        			Rats*
		                        			;
		                        		
		                        			Rats, Sprague-Dawley
		                        			;
		                        		
		                        			Receptors, Androgen*
		                        			;
		                        		
		                        			Superoxide Dismutase
		                        			;
		                        		
		                        			Testis
		                        			;
		                        		
		                        			Testosterone
		                        			;
		                        		
		                        			Water
		                        			;
		                        		
		                        			Weights and Measures
		                        			
		                        		
		                        	
8.Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer.
Dong Wan KIM ; Hoon Gu KIM ; Joo Hang KIM ; Keunchil PARK ; Hoon Kyo KIM ; Joung Soon JANG ; Bong Seog KIM ; Jin Hyoung KANG ; Kyung Hee LEE ; Sang We KIM ; Hun Mo RYOO ; Jin Soo KIM ; Ki Hyeong LEE ; Jung Hye KWON ; Jin Hyuk CHOI ; Sang Won SHIN ; Seokyung HAHN ; Dae Seog HEO
Cancer Research and Treatment 2019;51(1):119-127
		                        		
		                        			
		                        			PURPOSE: This randomized phase III study was designed to compare the efficacy and safety of irinotecan plus cisplatin (IP) over etoposide plus cisplatin (EP) in Korean patients with extensive-disease small-cell lung cancer (SCLC). MATERIALS AND METHODS: Patients were randomly assigned to receive IP, composed of irinotecan 65 mg/m2 intravenously on days 1 and 8+cisplatin 70 mg/m2 intravenously on day 1 every 3 weeks, or EP, composed of etoposide 100 mg/m2 intravenously on days 1, 2, 3+cisplatin 70 mg/m2 intravenously on day 1, every 3 weeks for a maximum of six cycles, until disease progression, or until unacceptable toxicity occurred. The primary endpoint was overall survival. RESULTS: A total of 362 patients were randomized to IP (n=173) and EP (n=189) arms. There were no significant differences between IP and EP arms for the median overall survival (10.9 months vs. 10.3 months, p=0.120) and the median progression-free survival (6.5 months vs. 5.8 months, p=0.115). However, there was a significant difference in response rate (62.4% vs. 48.2%, p=0.006). The pre-planned subgroup analyses showed that IP was associated with longer overall survival in male (11.3 months vs. 10.1 months, p=0.036), < 65 years old (12.7 months vs. 11.3 months, p=0.024), and Eastern Cooperative Oncology Group performance status 0/1 (12.4 months vs. 10.9 months, p=0.040) patient groups. The severity of treatment-related adverse events such as grade 3/4 anemia, nausea and diarrhea was more frequent in patients treated with IP. CONCLUSION: The IP chemotherapy did not significantly improve the survival compared with EP chemotherapy in Korean patients with extensive-disease SCLC.
		                        		
		                        		
		                        		
		                        			Anemia
		                        			;
		                        		
		                        			Arm
		                        			;
		                        		
		                        			Cisplatin*
		                        			;
		                        		
		                        			Diarrhea
		                        			;
		                        		
		                        			Disease Progression
		                        			;
		                        		
		                        			Disease-Free Survival
		                        			;
		                        		
		                        			Drug Therapy
		                        			;
		                        		
		                        			Etoposide*
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Lung Neoplasms
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Nausea
		                        			;
		                        		
		                        			Small Cell Lung Carcinoma*
		                        			
		                        		
		                        	
9.A Study of Factors Influencing Subjective Memory Complaints among Community Dwelling Elderly.
Ui Sub LEE ; Young Myo JAE ; Sae Heon JANG ; Jin Hyuk CHOI ; Kyoung Hwan LEE
Journal of Korean Geriatric Psychiatry 2018;22(1):19-24
		                        		
		                        			
		                        			OBJECTIVE: We examined the factors influencing subjective memory complaints among community dwelling elderly in urban area. METHODS: The subjects of this research were 160 community-dwelling elderly people without dementia and major depressive disorder. The questionnaires regarding the socio-demographic characteristics were conducted by each person. They include Korean version of Subjective Memory Complaints Questionnaires (SMCQ), Korean version of Short Geriatric Depression Scale (SGDS-K) and Korean version of Mini-Mental State Examination (K-MMSE). Subjective memory complaints were defined as above 4 points of SMCQ. RESULTS: 39.38% of the subjects had subjective memory complaints. There were significant associations between subjective memory complaints and SGDS-K (p < 0.001), physical illness (p=0.001), but there was no association with K-MMSE (p=0.383). CONCLUSION: There is a discrepancy between subjective memory complaints and actual cognitive impairments. This discrepancy suggests that the depressive disorders including minor depressive disorder and subsyndromal depression, might play a role in the subjective memory complaints rather than actual cognitive impairments in community-dwelling elderly people. Therefore, the treatments for the depressive disorders should be considered in dealing with the subjective memory complaints.
		                        		
		                        		
		                        		
		                        			Aged*
		                        			;
		                        		
		                        			Cognition Disorders
		                        			;
		                        		
		                        			Dementia
		                        			;
		                        		
		                        			Depression
		                        			;
		                        		
		                        			Depressive Disorder
		                        			;
		                        		
		                        			Depressive Disorder, Major
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Independent Living*
		                        			;
		                        		
		                        			Memory*
		                        			
		                        		
		                        	
10.Predictive Factors for Improvement of Atrophic Gastritis and Intestinal Metaplasia: A Long-term Prospective Clinical Study
Young Jae HWANG ; Nayoung KIM ; Chang Yong YUN ; Min Gu KWON ; Sung Min BAEK ; Yeong Jae KWON ; Hye Seung LEE ; Jae Bong LEE ; Yoon Jin CHOI ; Hyuk YOON ; Cheol Min SHIN ; Young Soo PARK ; Dong Ho LEE
The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2018;18(3):186-197
		                        		
		                        			
		                        			BACKGROUND/AIMS: To investigate the predictive factors for improvement of atrophic gastritis (AG) and intestinal metaplasia (IM). MATERIALS AND METHODS: A total of 778 subjects were prospectively enrolled and followed up for 10 years. Histological analysis of AG and IM was performed by using the updated Sydney system. To find the predictive factors for reversibility of AG and IM, 24 factors including genetic polymorphisms and bacterial and environmental factors were analyzed. RESULTS: In all subjects, the predictive factor by multivariate analysis for improvement of both antral and corpus AG was successful eradication. The predictive factors for improvement of antral IM were age and successful eradication. The predictive factor for improvement of corpus IM was successful eradication. In patients with Helicobacter pylori infection, age and cagA were predictive factors for improvement of AG and IM. In patients with H. pylori eradication, monthly income and cagA were predictive factors for improvement of AG and IM. CONCLUSIONS: H. pylori eradication is an important predictive factor of regression of AG and IM and would be beneficial for the prevention of intestinal-type gastric cancer. Young age, high income, and cagA are additional predictive factors for improving AG and IM status. Thus, various factors affect the improvement of AG and IM.
		                        		
		                        		
		                        		
		                        			Clinical Study
		                        			;
		                        		
		                        			Gastritis, Atrophic
		                        			;
		                        		
		                        			Helicobacter pylori
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Metaplasia
		                        			;
		                        		
		                        			Multivariate Analysis
		                        			;
		                        		
		                        			Polymorphism, Genetic
		                        			;
		                        		
		                        			Prospective Studies
		                        			;
		                        		
		                        			Stomach Neoplasms
		                        			
		                        		
		                        	
            
Result Analysis
Print
Save
E-mail